Study Tracks Factors That Increase Risk of Ocular MG Generalization
In people with ocular myasthenia gravis (OMG), disease onset during adulthood, the presence of nerve abnormalities, anti-acetylcholine receptor (AChR)…
Articles by Marta Figueiredo, PhD
MG Genetic Risk Factor Directly Tied to Neuromuscular Junction Identified
For the first time, a genetic risk factor for myasthenia gravis (MG) has been identified that involves a gene — AGRN…
Efgartigimod Being Considered as Generalized MG Therapy for Europe
The European Medicines Agency (EMA) has agreed to review Argenx’s application requesting the approval of its lead candidate,…
Batoclimab Effective and Safe With Generalized MG, Phase 2 Trial Finds
Harbour BioMed’s investigational therapy batoclimab (HBM9161) safely and rapidly eases symptoms and lowers the levels of harmful antibodies in…
Standard MG Care Less Effective for Women, Danish Study Suggests
Women with myasthenia gravis (MG) given standard treatment improve significantly less in both objective and patient-reported outcome measures than…
Response to Soliris May Take Longer Than 3 Months for Some With gMG
Most generalized myasthenia gravis (gMG) patients respond to Soliris (eculizumab) within three months of treatment, but some have to wait…
#AANAM – Study Examines Seronegative Characteristics
Editor’s note: The Myasthenia Gravis News team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April…
#AANAM – Nipocalimab Safely Eases gMG Symptoms, Final Trial Data Confirm
Editor’s note: The Myasthenia Gravis News team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April…
#AANAM – Rituximab Effective in Real World in Adults With Refractory gMG
Editor’s note: The Myasthenia Gravis News team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April…
2 Pro-inflammatory T-cell Subsets Linked to Disease Severity in Study
Blood levels of two pro-inflammatory subsets of immune T-cells are abnormally low in people with myasthenia gravis (MG) who…